GND 004
Alternative Names: anti-RAMP2 Ab - Kidswell Bio; GND-004Latest Information Update: 05 Dec 2023
At a glance
- Originator Kidswell Bio
- Class Antibodies; Eye disorder therapies
- Mechanism of Action Receptor activity-modifying protein 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Retinopathy of prematurity
Most Recent Events
- 08 Nov 2023 GND 004 is available for licensing as of 08 Nov 2023. https://www.kidswellbio.com/en/pipeline/
- 08 Nov 2023 Preclinical trials in Retinopathy of prematurity in Japan (unspecified route) (Kidswell Bio pipeline, November 2023)
- 31 Dec 2022 Kidswell Bio has patent protection for GND 004 in Japan